SynBiotic SE (FRA:SBX)

Market Cap	10.91M -50.4%
Revenue (ttm)	3.86M -52.7%
Net Income	-10.63M
EPS	-2.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,278
Open	1.570
Previous Close	1.590
Day's Range	1.570 - 1.700
52-Week Range	1.552 - 3.645
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About SynBiotic SE

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany.

• Industry: Pharmaceutical Preparations
• Founded: 2017
• Employees: 55
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: SBX

Financial Performance

In 2023, SynBiotic SE's revenue was 3.86 million, a decrease of -52.71% compared to the previous year's 8.17 million. Losses were -10.63 million, -56.36% less than in 2022.